Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 4,614 shares at $138.70 ($636K) on 2018-05-14, disclosed to the SEC on 2018-05-16.
Open-market sale of $636k LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $134.25 | 241 | $32K | 5.1% |
| 2 | $137.50 | 600 | $83K | 13.0% |
| 3 | $138.70 | 691 | $96K | 15.1% |
| 4 | $138.70 | 691 | $96K | 15.1% |
| 5 | $139.45 | 9 | $1K | 0.2% |
| 6 | $133.35 | 200 |
| $27K |
| 4.2% |
| 7 | $135.78 | 300 | $41K | 6.4% |
| 8 | $138.35 | 841 | $116K | 18.3% |
| 9 | $138.35 | 841 | $116K | 18.3% |
| 10 | $139.04 | 200 | $28K | 4.4% |
| Total | $137.78 avg | 4,614 | $636K | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |